# Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

> **NCT00003715** · PHASE2 · TERMINATED · sponsor: **AVAX Technologies** · enrollment: 425 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** BCG vaccine
- **BIOLOGICAL:** autologous tumor cell vaccine
- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** chemotherapy
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00003715
- **Lead sponsor:** AVAX Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 425 (ESTIMATED)
- **Why stopped:** Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003715, "Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00003715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*